Puma Biotechnology (NASDAQ: PBYI) shares have soared 34% in three months. A deep dive into its robust Return on Equity and earnings growth reveals the financial engine behind the rally, even as analysts signal future headwinds.
Vir Biotechnology shifts strategic focus, partnering with Astellas Pharma to advance its immuno-oncology candidate VIR-5500 for metastatic prostate cancer. The deal brings substantial funding and industry validation, placing Vir's execution and the asset's clinical promise under intense scrutiny.
Puma Biotechnology (PBYI) closed fiscal 2025 with robust revenue growth and provided a confident outlook for its key drug Nerlynx, despite navigating prescription headwinds and preparing for pivotal clinical trial readouts in 2026.
At its strategy conference, Kerry Group detailed a roadmap to leverage biotechnology and digital transformation to drive volume growth and expand margins, reaffirming its ambitious 19-20% EBITDA target for 2028 amidst a dynamic global food market.
A deadly explosion at a biotechnology facility in China's Shanxi province has resulted in eight fatalities, prompting an official investigation and the detention of the company's legal representative.
French fragrance and flavor leader Robertet (ENXTPA:RBT) has taken an equity stake in Aethera Biotech, expanding their partnership and marking a decisive push into biotechnology for cosmetic actives. The move aims to develop next-generation natural ingredients and could redefine the company's growth trajectory in the competitive beauty market.
Sana Biotechnology's novel cell therapy has demonstrated unprecedented results in a Type 1 diabetes patient, sparking a bullish investment thesis centered on its technological edge and platform potential beyond the landmark achievement.
Nautilus Biotechnology reports robust fourth-quarter financial performance and provides strategic updates on its mission to map the human proteome, signaling a pivotal year ahead for the life sciences firm.
Puma Biotechnology reported robust fourth-quarter revenue of $75.5 million, fueled by its flagship breast cancer drug Nerlynx and a significant surge in royalties. While navigating typical seasonal inventory patterns, the company outlined aggressive plans for its alisertib clinical programs and provided 2026 guidance.
Sana Biotechnology appoints Brian Piper as its new finance chief, placing an experienced hand at the helm as the pre-revenue biotech navigates a rich valuation, mounting losses, and a critical cash runway.
Shares of Vir Biotechnology surged nearly 28% following a major collaboration with Japan's Astellas Pharma for its experimental prostate cancer therapy VIR-5500. The partnership, buoyed by encouraging early-stage clinical data, has reignited investor debate over the biotech's valuation and long-term prospects amidst a history of financial losses.
Once focused on infectious diseases, Vir Biotechnology sees its strategic shift toward cancer research validated by a new alliance with Astellas and early clinical results for its 'masked' T cell engager, VIR-5500, showing potent activity and a manageable safety profile in prostate cancer.
The regenerative medicine firm, specializing in 3D bioprinting, is forecast to turn its first profit in 2028. With a debt-free balance sheet and aggressive growth projections, investors are weighing the timeline against the company's pioneering technology.
Buoyed by a robust 2025 performance, Genmab executives project a pivotal 2026 filled with critical clinical readouts, setting the stage for multiple potential drug launches in 2027 that could solidify its standing as a leading independent oncology company.
Sarepta Therapeutics initiates a study to assess a sirolimus-based regimen aimed at mitigating liver injury risks associated with its Duchenne gene therapy Elevidys. Meanwhile, Sana Biotechnology reports sustained insulin production in a Type 1 diabetes patient 14 months after receiving its experimental cell therapy. Additional updates cover Bayer, Inovio, and Unnatural Products.
Biotechnology firm Halozyme Therapeutics appoints David Ramsay as interim Chief Financial Officer, aiming to ensure financial stability during a leadership transition. The move comes as the company navigates recent stock market pressure while building on its long-term growth trajectory.
In a strategic move to tap into Asia's burgeoning biotech innovation, Eli Lilly partners with Samsung Biologics to establish 'Gateway Labs Korea,' a first-of-its-kind incubator outside the United States aimed at nurturing early-stage life sciences startups.
Biotech firm Protara Therapeutics reported a fourth-quarter net loss of $17.3 million, falling short of analyst projections, while continuing to invest in its novel cell therapy and oncology programs.
Amgen announces the completion of its Phase 3 trial for ABP 206, a potential biosimilar to Opdivo, marking a significant step toward offering a more affordable immunotherapy option for advanced melanoma patients.
In a move to secure sustainable ingredient supplies and bolster its innovation pipeline, French fragrance and flavor leader Robertet has entered a phased investment and joint venture with Italian plant-based biotech firm Aethera.
